Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0001209191-24-000807 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-04 | 2024-01-02 | TSHA | Nolan Sean P. | CEO, Dir | A - Grant | $0.00 | +1.18M | 1.19M | +101,255% | $0 |
| D | 2024-01-04 | 2024-01-02 | TSHA | Nolan Sean P. | CEO, Dir | A - Grant | $0.00 | +1.18M | 1.18M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | A | A | 1,184,688 | $0.00 | 1,185,858 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2024-01-02 | A | A | 1,184,688 | $0.00 | 1,184,688 | D | $1.71 · — to 2034-01-02 | 1,184,688 Common Stock | (F3) 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |